GAITHERSBURG, Md., April 1,
2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a
global company advancing protein-based vaccines with its Matrix-M™
adjuvant, will showcase continued progress on data from its updated
COVID-19 vaccine (NVX-CoV2601) and provide an overview of its
influenza and COVID-19-Influenza Combination (CIC) vaccine
candidates at the World Vaccine Congress 2024 (WVC)
in Washington, DC, April 2 to 4, 2024.
New data from Novavax's ongoing research on its updated XBB.1.5
COVID-19 vaccine in participants who previously received an mRNA
vaccine showed robust neutralizing antibody titers for the XBB.1.5
subvariant as well as for the currently circulating JN.1
subvariant. Data also showed that the vaccine's safety and
reactogenicity profile was consistent with its prototype vaccine
(NVX-CoV2373).
Differences observed in immunoglobulin (IgG) subclass
responses and Fcγ-mediated effector functions following mRNA and
protein-based COVID-19 vaccinations will be shared.
Novavax will also discuss its influenza and CIC vaccine
candidates, including a recap of data to date and the timeline for
the Phase 3 trial anticipated to start during the second half of
2024.
Dr. Robert Walker, Chief Medical
Officer, Novavax, will participate in a panel discussion on The
Future of COVID-19 Vaccinations on April
3, exploring the benefits of developing broadly protective
antigens or combination vaccines.
Novavax presentations during WVC:
Mallory, R
|
Safety and
Immunogenicity of the
Novavax XBB.1.5 SARS-
CoV-2 Vaccine in
Previously mRNA
Vaccinated Participants
|
Oral
Presentation
April 3,
2024
10:10am
(EDT)
|
Kalkeri, R
|
Distinct Differences
in
IgG4 switch and Fc
effector functions
between mRNA and
Novavax protein-based
COVID Vaccination
|
Oral
Presentation
April 3,
2024
10:25am
(EDT)
|
Mallory, R
|
Update on Novavax
influenza and COVID-
influenza combination
vaccine
|
Oral
Presentation
April 3,
2024
2:40pm (EDT)
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to help protect against serious infectious
diseases. Novavax, a global company based in Gaithersburg,
Md., U.S., offers a differentiated vaccine platform that combines a
recombinant protein approach, innovative nanoparticle technology
and Novavax's patented Matrix-M adjuvant to enhance the immune
response. The Company's portfolio includes its COVID-19 vaccine and
its pipeline includes a vaccine for COVID-19 and influenza
combined. In addition, Novavax's adjuvant is included in the
University of Oxford and Serum
Institute of India's R21/Matrix-M
malaria vaccine. Please visit novavax.com and
LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-presents-data-on-updated-covid-19-vaccine-and-progress-to-date-on-its-covid-19-influenza-combination-vaccine-candidate-at-world-vaccine-congress-2024-302104444.html
SOURCE NOVAVAX, INC